New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Vitruvia Medical AG · ISIN: CH0461931419 · EQS - adhoc news (21 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1452625
30 September 2022 09:30AM

Vitruvia Medical AG: Half-year results as of 30.6.2022 incl. half-year report


EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Half Year Results/Interim Report
Vitruvia Medical AG: Half-year results as of 30.6.2022 incl. half-year report

30-Sep-2022 / 09:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Vitruvia Medical AG: Half-year results as of 30.6.2022 incl. half-year report

Anglikon, 30 September 2022: Vitruvia Medical AG generated revenues of approximately EUR 0.66 million in the first six months of the financial year. Earnings before interest, taxes, depreciation and amortisation amounted to EUR 21,077.00. It should be noted that the disposal of the two subsidiaries was written off, which had a negative impact on earnings.

Due to the delayed certification of the FFP2 masks, Vitruvia Medical AG expects for the financial year 2022 for LT technologies GmbH & Co. KG for the 2022 financial year of around EUR 1.85 million and an operating result of EUR 0.254 million. Both figures therefore do not yet include the revenue/profit from mask production.

The half-year report as of 30 June 2022 of Vitruvia Medical AG (Group) and the half-year financial statements as of 30 June 2022 Vitruvia Medical AG (Group) are published on the website of Vitruvia Medical AG (www.vitruvia-med.com).

 

About Vitruvia Medical AG:

Vitruvia Medical AG is a Swiss investment company focusing on the repair, production and trade of medical devices as well as surgical instruments.

Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success.


30-Sep-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Vitruvia Medical AG
Kesselackerstr. 18
5611 Anglikon
Switzerland
Phone: +41 44 915 33 78
E-mail: kontakt@vitruvia-med.com
Internet: www.vitruvia-med.com
ISIN: CH0461931419
WKN: A2PDWF
Listed: Regulated Unofficial Market in Munich
EQS News ID: 1452625

 
End of Announcement EQS News Service

1452625  30-Sep-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1452625&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.